Study title:
Tucker-M-A, Meadows-A-T, Boice-Jr-J-D, et-al.
Epidemiology and Biostatistics Program, Division of Cancer Etiology, National Cancer Institute, National Institutes of Health, Public Health Service, U.S. Department of Health and Human Services, Bethesda, MD 20892, United States.
Leukemia after therapy with alkylating agents for childhood cancer.
Journal of the National Cancer Institute {J-NATL-CANCER-INST}, 1987, Vol/Iss/Pg. 78/3 (459-464).Tucker-M-A, Meadows-A-T, Boice-Jr-J-D, et-al.
Epidemiology and Biostatistics Program, Division of Cancer Etiology, National Cancer Institute, National Institutes of Health, Public Health Service, U.S. Department of Health and Human Services, Bethesda, MD 20892, United States.
Leukemia after therapy with alkylating agents for ...
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Neoplasms [C04]
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: PROCARBAZINE |
ATC code: |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|